Medicine details
| Image |  |
| Name | Sorafen |
| Dosage | Tablet |
| Generic Name | Sorafenib |
| Classes |
Anticancer/Antineoplastic Agent Multikinase Inhibitor/VEGF/VEGFR Inhibitor |
| Diseases |
Cancer Kidney Cancer Liver Cancer Thyroid Cancer |
| Company | Techno Drugs Ltd. |
Drug Package Details
| Strength | 200 mg |
| Storage Condition | |
| Origin Country | Bangladesh |
| Commercial Pack | 1 |
| Price per pack | ৳ 300.00 |
| Cost per pack | ৳ 264.00 |
| Package unit | 4 tabs strip |
| Price per unit | ৳ 300.00 |
| Cost per unit | ৳ 264.00 |
| Discount | 0 |
| Coupon | |
| Remarks |
Sorafenib
Sorafenib belongs to the class of kinase inhibitors. Its mechanism of action involves inhibiting multiple kinases involved in tumor cell proliferation and angiogenesis. Specifically, it targets Raf kinase, VEGFR (vascular endothelial growth factor receptor), and PDGFR (platelet-derived growth factor receptor).
Sorafenib is a kinase inhibitor indicated for the treatment of
- Unresectable hepatocellular carcinoma
- Advanced renal cell carcinoma
- Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
- 400 mg (2 tablets) orally twice daily without food.
- Treatment interruption and/or dose reduction may be needed to manage adverse reactions.
- Cardiovascular Events: Consider temporary or permanent discontinuation of Sorafenib.
- Bleeding: Discontinue Sorafenib if needed.
- Hypertension: Monitor blood pressure weekly during the first 6 weeks and periodically thereafter.
- Dermatologic Toxicities: Interrupt and/or decrease dose. Discontinue for severe or persistent reactions, or if Stevens-Johnson syndrome and toxic epidermal necrolysis is suspected.
- Gastrointestinal Perforation: Discontinue Sorafenib.
- QT Prolongation: Monitor electrocardiograms and electrolytes in patients at increased risk for ventricular arrhythmias.
- Drug-Induced Liver Injury: Monitor liver function tests regularly; discontinue for unexplained transaminase elevations.
- Embryo-Fetal Toxicity: Sorafenib may cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
- Impairment of TSH suppression in DTC: Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer.
Contraindication
- Sorafenib is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of Sorafenib.
- Sorafenib in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer
None known.
None known.
Bangla
English